Modulating the Gut‐Microbiota‐Brain Axis in Alzheimer's Disease: Therapeutic Potential of Nutritional and Metabolic Factors Authors: Binyue Xu, Xuhuan Li, Shangling Dong, Zheyuan Zhang, Dong Jin, Guoping Li, Jiesheng Wang Published: 2026 ABSTRACT ABSTRACTBackgroundAlzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia among the elderly, characterized by a gradual decline in memory and cognitive function. The growing body of evidence highlighting the interaction between the gut microbiota and the central nervous system has positioned the gut microbiota as a key area of research in AD pathogenesis.MethodsThis review critically evaluates the preclinical evidence and clinical trial outcomes, complemented by mechanistic studies and Mendelian randomization analyses, to assess the therapeutic potential of nutritional interventions targeting the gut‐microbiota‐brain axis in AD.ResultsDietary components and patterns regulate the composition and function of the gut microbiota, which in turn influence brain function through the gut‐microbiota‐brain axis via chemical/metabolic, immune‐mediated, and neural pathways. Specific nutrients, microbial metabolites, and dietary patterns have been shown to exert either protective or detrimental effects on AD pathology and cognitive function. Emerging strategies, including precision nutrition, fecal microbiota transplantation, and next‐generation microbiome‐based therapies, offer new avenues for AD prevention and treatment.ConclusionsNutritional interventions targeting the gut‐microbiota‐brain axis represent a promising approach for the comprehensive prevention and management of AD. Further mechanistic and clinical studies are warranted to translate these findings into effective therapeutic strategies. Abbreviations 5‐hydroxytryptamine (serotonin) Alzheimer's disease alternate‐day fasting aryl hydrocarbon receptor artificial intelligence APPswe/PS1dE9 transgenic mouse model all‐trans retinoic acid blood–brain barrier cellular communication network factor 2 cluster of differentiation 4 positive helper T cells leukocyte common antigen Clostridioides difficile infection central nervous system cerebrospinal fluid Dietary Approaches to Stop Hypertension docosahexaenoic acid docosapentaenoic acid eicosapentaenoic acid U.S. Food and Drug Administration flavin monooxygenase 3 fecal microbiota transplantation gamma‐aminobutyric acid hypoxia‐inducible factor 1‐alpha hypothalamic–pituitary–adrenal axis indole‐3‐acetic acid intermittent fasting interleukin indole‐3‐lactic acid indole‐3‐propionic acid ketogenic diet microtubule‐associated protein 1A/1B‐light chain 3B lipopolysaccharide mild cognitive impairment monocyte chemoattractant protein medium‐chain triglycerides Mediterranean diet major histocompatibility complex class II positive Mediterranean‐DASH Intervention for Neurodegenerative Delay Mini‐Mental State Examination monocytic myeloid‐derived suppressor cells Montreal Cognitive Assessment Mendelian randomization studies mammalian target of rapamycin nuclear factor kappa‐light‐chain‐enhancer of activated B cells N‐3 polyunsaturated fatty acids outer membrane protein A outer membrane vesicles sequestosome 1 periodic fasting phosphorylated tau randomized controlled trials senescence‐accelerated mouse‐prone short‐chain fatty acids sirtuin 1 spleen tyrosine kinase synthetic microbial communities transforming growth factor Toll‐like receptor trimethylamine trimethylamine‐N‐oxide tumor necrosis factor triggering receptor expressed on myeloid cells time‐restricted feeding volatile fatty acids Introduction As the world enters a deeply aging society, the prevalence of Alzheimer's disease (AD) is becoming increasingly severe. AD is expected to affect 131 million individuals globally by the year 2050 [1]. Studies indicate that the prevalence of AD doubles every 5 years as age increases [2]. This increasing prevalence poses major threats to the physical and mental health as well as the quality of life of the elderly population, emerging as a significant public health challenge at present. The pathogenesis of AD is multifactorial, complex, and not yet fully elucidated, involving genetic predisposition, lifestyle factors, and environmental influences, among others. Existing research indicates that the characteristic pathological hallmarks of AD primarily include the abnormal extracellular deposition of amyloid‐β (Aβ), forming senile plaques, and the hyperphosphorylation of the microtubule‐associated protein tau, leading to the formation of neurofibrillary tangles and neuronal loss within neurons [3]. These pathological changes are accompanied by gliosis, which further contributes to the progression of AD. Despite the proliferation of research on AD‐related mechanisms, there is still no complete cure for AD, and the need to prevent or delay AD and mild cognitive impairment (MCI) progression remains unmet. Therefore, the management of potential risk factors is currently considered the most effective approach for preventing dementia, AD, and MCI [4, 5, 6]. Both clinical research and expert consensus have indicated that nutritional intervention plays an important role in maintaining brain health, modulating risk factors, delaying disease progression, and improving overall prognosis [7, 8]. The 2011 National Institute on Aging‐Alzheimer's Association (NIA‐AA) guidelines demonstrated a direct relationship between diet and changes in brain structure and activity [9]. The potential role of diet in preventing or slowing neurodegeneration or enhancing certain cognitive abilities has thus become a major focus of research in both preclinical stages and clinical research. As the roles of gut microbiota in aging, immunity, and metabolism continue to be elucidated, numerous studies have found that gut microbiota dysbiosis is prevalent in AD‐related cognitive impairment [10, 11]. Consequently, the involvement of gut microbiota composition and its metabolites in the pathogenesis of AD development through the “Gut‐Microbiota‐Brain Axis” has become a major research focus in recent years, also providing novel directions and approaches for AD therapeutic strategies. Research indicates that diet and specific nutrients can influence the composition of the gut microbial community [12] and amyloid production or aggregation [13, 14]. Modulating the gut microbiota through specific nutritional interventions and the use of probiotics, fecal microbiota transplantation (FMT) and next‐generation microbiome‐based therapies may effectively reduce AD‐associated chronic inflammation and Aβ levels, thereby preventing or ameliorating AD symptoms. Methods Relevant literature was retrieved from the PubMed and Web of Science, covering the publication period from database inception to February 2026. This review included clinical trials, observational studies, and experimental studies conducted on animal models that explored the mechanistic links between nutritional interventions, gut microbiota modulation, and AD pathology. Studies focusing on MCI, prodromal AD, or preclinical stages of AD were also considered for inclusion, as these populations represent critical windows for nutritional interventions. Additionally, the reference lists of published systematic reviews and meta‐analyses were manually screened to identify additional eligible original studies not captured in the initial database searches. The search strategy incorporated the following keywords across three thematic domains, combined using Boolean operators (“AND” and “OR”), including but not limited to: 1. Alzheimer's disease and related cognitive decline: “Alzheimer's disease,” “mild cognitive impairment,” “MCI,” “amyloid beta,” “Aβ,” “tau protein.” 2. Gut microbiota: “gut microbiota,” “gut microbiome,” “gut microflora,” “microbiota‐gut‐brain axis,” “Bacteroidetes,” “Firmicutes,” “Proteobacteria.” 3. Nutritional interventions: “nutritional intervention,” “short‐chain fatty acids,” “n‐3 polyunsaturated fatty acids,” “polyphenols,” “trimethylamine‐N‐oxide,” “dietary patterns,” “Mediterranean diet,” “ketogenic diet,” “intermittent fasting.” Gut‐Microbiota‐Brain Axis in AD The human gut microbiota is predominantly composed of five bacterial phyla: Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia [15]. Among these, Bacteroidetes and Firmicutes constitute the majority of the gut bacterial community, while Proteobacteria and Actinobacteria are present in smaller proportions [16]. Accumulating evidence indicates that patients with cognitive impairment and cerebral amyloidosis exhibit alterations in gut microbiome composition [17, 18], suggesting a link between gut dysbiosis and neuroinflammation. Mechanistically, gut dysbiosis is thought to promote intestinal barrier disruption, facilitate the translocation of bacterial products, and ultimately influence Aβ metabolism and deposition in the brain [19, 20]. Bacteroidota Bacteroidota, particularly the genus Bacteroides, are Gram‐negative obligate anaerobes that ferment carbohydrates to produce volatile fatty acids (VFAs), which serve as a major energy source for colonocytes and modulate intestinal homeostasis [21, 22, 23, 24]. Their abundance is strongly influenced by diet: an animal‐based or high‐fat/low‐fiber diet increases Bacteroides levels, whereas a plant‐based diet is associated with lower abundance [25, 26]. Studies have reported lower Bacteroides abundance in AD patients [17, 27, 28], likely due to its protective role: its certain metabolites such as acetate and propionate inhibit pro‐inflammatory cytokine release, maintain intestinal barrier and blood–brain barrier (BBB) integrity, and suppress Aβ deposition [29, 30]. Beyond VFAs, Bacteroidota‐derived serine‐glycine (S/G) lipids have been shown to suppress monocyte proinflammatory responses by maintaining expression of NF‐κB and TLR pathway inhibitors, including Trem2, a mechanism that may also be relevant to microglial function in AD [31]. Within the same phylum, increased abundance of Parabacteroides has also been shown to reduce AD risk by elevating serum alanine levels [32]. Conversely, under conditions of increased gastrointestinal and BBB permeability, which are common in aging and AD, Bacteroides‐derived lipopolysaccharide (LPS) and proteolytic peptides can impair microglia‐mediated innate immunity, phagocytosis, and detoxification, while also promoting Aβ production, thereby sustaining chronic and progressive neuroinflammation [11, 33, 34, 35]. In vivo studies confirm that oral administration of Bacteroides fragilis suppresses microglial Aβ clearance [36] and activates microglia in neuronal C/EBPβ transgenic mice [37, 38]. These discrepant findings may arise from differences in sample size, study design, host species, confounding factors, and interactions with other microbial communities. Notably, a longitudinal study in AD mice revealed that Bacteroides abundance increased over time, with compositional differences detectable as early as 8 weeks of age, which precedes the onset of cognitive deficits and amyloid pathology. This temporal pattern suggests that the direction of microbial change may depend on disease stage and that early microbiota alterations may precede overt pathology, adding further complexity to the interpretation of cross‐sectional findings [39]. The dual roles of Bacteroidetes in AD [40], together with their known responsiveness to diet, raise the possibility that dietary modulation could influence AD pathogenesis. Future research integrating multi‐omics approaches and longitudinal tracking is needed to resolve current contradictions and identify strain‐specific therapeutic targets. Firmicutes Firmicutes play a crucial role in maintaining host homeostasis. Many members of this phylum, including Bacillus and Lactobacillus, are widely recognized as probiotics [41]. Firmicutes utilize dietary fiber to produce short‐chain fatty acids (SCFAs) such as acetate, butyrate, and lactate [42], which exert beneficial effects on cognition through anti‐inflammatory, antioxidant, and insulin‐sensitizing mechanisms [43, 44]. Multiple cohort studies have consistently reported a reduced proportion of Firmicutes in AD patients [45, 46, 47]. Within this phylum, genera such as Roseburia and Faecalibacterium have been positively correlated with MMSE and MoCA scores [45]. Similarly, the anti‐inflammatory species Eubacterium rectale (class Clostridia) shows decreased abundance in cognitively impaired individuals with cerebral amyloidosis [17]. Animal studies have confirmed the neuroprotective potential of multiple Firmicutes species through diverse mechanisms, including SCFA modulation, regulation of Tau phosphorylation, suppression of neuroinflammation, activation of antioxidant defenses, and direct inhibition of Aβ aggregation [48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59]. Notably, not all Firmicutes species uniformly decline. Ruminococcus gnavus was enriched in older adults with cognitive impairment and inversely correlated with MMSE scores. Monocolonization of aged pseudo‐germ‐free mice with R. gnavus impaired learning and memory, accompanied by suppressed autophagy markers (decreased LC3B and Beclin‐1, increased P62) [60]. Likewise, Blautia coccoides and Lactobacillus murinus have also been associated with exacerbated AD pathology [61, 62], suggesting that species‐specific effects within the same phylum may oppose the general protective trend. The association between Firmicutes and cognitive function, together with their responsiveness to dietary fiber, supports the potential of fiber‐based nutritional strategies to modulate this phylum. Future studies are needed to clarify the specific roles of different Firmicutes species and their underlying mechanisms. Proteobacteria The Proteobacteria phylum comprises a diverse assemblage of Gram‐negative bacteria, including the families Enterobacteriaceae (Escherichia, Klebsiella), Desulfovibrionaceae, and Vibrionaceae, as well as the family Helicobacteraceae (e.g., the gastric colonizer Helicobacter pylori ). Through their predominantly pro‐inflammatory properties, members of this phylum have been implicated in the pathogenesis of neurodegenerative disorders via the gut‐brain axis. Multiple cross‐sectional studies have consistently reported an elevated abundance of Proteobacteria in AD patients. Gammaproteobacteria and Enterobacteriales progressively enriched from healthy controls to prodromal MCI and AD stages [45]. Notably, cognitively normal individuals with cerebral Aβ deposition (CN+) exhibited a significantly lower abundance of class Deltaproteobacteria compared to those without Aβ deposition (CN−), suggesting that alterations in Proteobacteria subclasses may precede clinical symptoms [63]. Mechanistic evidence from animal models supports a causal role for multiple Proteobacteria species. Enterobacteria infection exacerbated neurodegeneration in a Drosophila AD model [64]. In mouse experiments, several Proteobacteria species have been shown to exacerbate AD‐related pathology and cognitive decline through mechanisms involving microbial translocation, immune activation, and microglial dysfunction [65, 66, 67, 68]. Outer membrane vesicles (OMVs) derived from Helicobacter pylori (Hp) have been shown to cross biological barriers and enter the brain, leading to glial activation, neuronal dysfunction, and exacerbated Aβ pathology [69]. The translational relevance of these findings is underscored by direct evidence from human brain tissues. LPS derived from Escherichia coli is enriched in the hippocampus and neocortex, where it colocalizes with Aβ1–40/42 within amyloid plaques. Additionally, E. coli K99 pili protein was detected specifically in neuron‐like cells, suggesting that bacterial components can access the brain parenchyma and participate in plaque‐associated pathology [70, 71]. However, strain‐level heterogeneity exists within this phylum: the probiotic Escherichia coli Nissle 1917 exerted protective effects via outer membrane protein A (OmpA)‐containing OMVs that were internalized by glia and neurons, suppressing glial hyperactivation and restoring synaptic function in APP/PS1 mice. These findings provide insights into how probiotic‐derived OMVs modulate neuroimmune crosstalk in the CNS, establishing a mechanistic foundation for developing OMV‐based therapeutic strategies for AD [72]. Mendelian Randomization Studies (MR) Observational studies have consistently reported associations between gut microbiota composition and AD. However, findings across studies are often inconsistent [73, 74], probably due to (1) confounding factors, such as diet, medications (e.g., antibiotics, proton pump inhibitors), and lifestyle; (2) reverse causation, as AD‐related pathological or behavioral changes may alter gut microbiota rather than the reverse; (3) methodological heterogeneity, including differences in 16S rRNA sequencing platforms, bioinformatic pipelines, and taxonomic classification; (4) small sample sizes; and (5) population restriction to single ethnic or geographic groups [75, 76]. Consequently, it remains unclear whether the observed associations reflect causal relationships. MR provides a complementary strategy. By using genetic variants as instrumental variables for modifiable exposures, MR is less susceptible to confounding and reverse causation and has been widely used to investigate causal relationships between exposures and outcomes [77]. As summarized in Table 1, multiple MR studies suggest that specific gut microbial taxa exert causal effects on AD risk. This genetic evidence supports the investigation of microbiome‐targeted nutritional interventions as a potential strategy for AD. TABLE 1Causal relationships between gut microbiota and AD in Mendelian randomization studies.PhylumMicrobiotaRanksOutcomeRef. Actinobacteria Actinobacteria PhylumIncrease[78, 79] Actinobacteria ClassIncrease[78, 80, 81, 82, 83, 84, 85, 86, 87] Actinobacteriota PhylumDecrease[88] Actinomycetales OrderIncrease[79] Bifidobacteriaceae FamilyIncrease[89] Bifidobacteriales OrderIncrease[89] Bifidobacterium GenusIncrease[79, 90] Bifidobacterium GenusDecrease[91] Bifidobacterium adolescentis SpeciesIncrease[79] Bifidobacterium angulatum SpeciesIncrease[79] Bifidobacterium bifidum SpeciesDecrease[80, 85] Bifidobacterium infantis SpeciesDecrease[88] Bifidobacterium kashiwanohense SpeciesIncrease[79] Bifidobacterium ruminantium SpeciesIncrease[79] Coriobacteriaceae FamilyIncrease[80, 85] Coriobacteriales OrderIncrease[80, 85, 92] Coriobacteriia ClassNs[87] Corynebacterium GenusDecrease[79] Eggerthella GenusDecrease[80, 85, 93] Slackia GenusDecrease[91, 94] Bacteroidota Alloprevotella GenusDecrease[32] Bacteroidaceae FamilyDecrease[80, 85, 92] Bacteroides GenusDecrease[32, 80, 85] Bacteroides sp002160055 SpeciesIncrease[88] Bacteroidia ClassNS[87] Parabacteroides GenusDecrease[32] Parabacteroides johnsonii SpeciesDecrease[79] Paraprevotella GenusDecrease[91] Prevotella GenusIncrease[32, 90] Firmicutes Acidaminococcus fermentans GenusIncrease[88] Agathobacter GenusDecrease[90] Allisonella GenusIncrease[89, 95] Allisonella GenusDecrease[96] Anaerotruncus GenusDecrease[80, 85, 95] Bacillales OrderDecrease[89, 95, 97] Bacilli ClassDecrease[80, 85] Bacilli ClassNS[87] Bacillus GenusDecrease[79] Bacillus Velezensis SpeciesDecrease[79] Blautia GenusDecrease[98] Butyrivibrio GenusDecrease[80, 85] CAG‐177 sp002451755 SpeciesDecrease[88] CAG‐194 GenusDecrease[79] CAG‐194 sp002441865 SpeciesDecrease[79] CAG‐269 sp002372935 SpeciesIncrease[88] CAG‐349 GenusDecrease[79] CAG‐449 GenusIncrease[79] CAG‐465 sp000433135 SpeciesDecrease[88] CAG‐485 sp002362485 SpeciesDecrease[79] CAG‐488 SpeciesDecrease[88] CAG‐81 sp000435795 SpeciesDecrease[79] CAG‐81 sp000435795 SpeciesIncrease[88] CAG‐826 GenusIncrease[79] CHKCI006 sp900018345 SpeciesDecrease[79] Clostridia ClassDecrease[80, 85, 87] Clostridiales OrderDecrease[80, 85] Clostridium asparagiforme SpeciesDecrease[80, 85] Clostridium E sporosphaeroides SpeciesDecrease[90] Clostridium innocuum group GenusDecrease[80, 85, 93] Clostridium M clostridioforme SpeciesIncrease[79] Clostridium P GenusDecrease[88] Defluviitaleaceae FamilyDecrease[95] Defluviitaleaceae UCG011 GenusIncrease[91, 96] Dialister GenusIncrease[84] Dorea GenusIncrease[99] Erysipelotrichia ClassNs[87] Eubacteriumbrachygroup SpeciesDecrease[83] Eubacterium callanderi SpeciesDecrease[79] Eubacterium Q GenusDecrease[88] Eubacterium R GenusDecrease[90] Eubacterium ventriosum group GenusIncrease[91] Eubacterium_hallii SpeciesIncrease[80, 92] Faecalibacterium GenusDecrease[81] Holdemanella GenusIncrease[32, 83] Holdemania massiliensis SpeciesIncrease[90] Intestinimonas GenusDecrease[80, 85, 89] Intestinimonas GenusIncrease[96] Intestinimonas massiliensis SpeciesDecrease[79] Intestinimonas massiliensis SpeciesIncrease[90] KLE1615 GenusIncrease[79] Lachnoclostridium GenusIncrease[81, 82] Lachnospiraceae FamilyDecrease[32, 79] Lachnospiraceae GenusDecrease[80] Lachnospiraceae FCS020 GenusDecrease[96] Lachnospiraceae FCS020 group GenusIncrease[89, 95] Lachnospiraceae (NK4A136 group) GenusDecrease[91, 94] LachnospiraceaeUCG004 GenusDecrease[85] Lactobacillaceae FamilyIncrease[80, 81, 82, 84, 85] Lactococcus GenusIncrease[83] Lawsonibacter sp900066645 SpeciesIncrease[79] Megamonas funiformis SpeciesDecrease[90] Megasphaera GenusIncrease[90] Negativicutes ClassIncrease[80, 85] Oscillibacter GenusDecrease[80, 92, 96] Oscillibacter_unclassified SpeciesDecrease[92] Oscillospira GenusIncrease[78, 83] Oscillospiraceae FamilyDecrease[80, 92] Paenibacillus J GenusIncrease[90] Phocea GenusDecrease[88] RUG472 sp900319345 SpeciesIncrease[79] Ruminiclostridium 6 GenusIncrease[81, 82] Ruminiclostridium 9 GenusDecrease[80, 81, 82, 85, 93] Ruminococcaceae UCG‐003 GenusIncrease[91] Ruminococcaceae UCG004 GenusIncrease[78] Ruminococcus GenusDecrease[32] Ruminococcus1 GenusDecrease[78, 83] Selenomonadales OrderIncrease[80, 85, 93] Sellimonas GenusIncrease[95, 97] Turicibacter GenusIncrease[79, 99] Turicibacter sp001543345 SpeciesDecrease[79] Turicibacteraceae FamilyDecrease[79] UBA2821 SpeciesIncrease[88] UBA3792 SpeciesDecrease[88] UBA6382 SpeciesIncrease[88] UBA9475 sp002161235 SpeciesIncrease[79] Veillonella GenusDecrease[89] Veillonella unclassified SpeciesIncrease[80, 85] Proteobacteria Alphaproteobacteria ClassNS[87] An7 UnclassifiedIncrease[88] Aureimonas GenusDecrease[79] Azorhizobium GenusDecrease[88] Betaproteobacteria ClassDecrease[83] Betaproteobacteria ClassIncrease[80, 85, 92] Betaproteobacteria ClassNS[87] Burkholderiales OrderIncrease[80, 85, 92] Citrobacter A GenusDecrease[90] Deltaproteobacteria ClassIncrease[78, 83] Deltaproteobacteria ClassNS[87] Desulfovibrio GenusIncrease[91, 94] Desulfovibrionaceae FamilyIncrease[76, 83, 97, 99] Desulfovibrionales OrderIncrease[76, 78, 83, 97, 99] Enterobacteriaceae FamilyDecrease[89] Enterobacteriales OrderDecrease[89] Gammaproteobacteria ClassNS[87] Hydrogenophaga GenusIncrease[90] Klebsiella A GenusDecrease[88] Klebsiella pneumoniae GenusDecrease[88] Pasteurellaceae FamilyIncrease[80, 85, 93] Pasteurellales OrderIncrease[80, 85] Pseudomonas aeruginosa SpeciesDecrease[90] Raoultella GenusIncrease[90] Sutterella GenusDecrease[32] Sutterellaceae FamilyIncrease[80, 85] Chlamydiota Parachlamydiales GenusIncrease[88] Spirochaetota Borreliaceae OrderDecrease[88] Treponema D GenusDecrease[88] Tenericutes Tenericutes PhylumDecrease[80] Mollicutes ClassDecrease[80, 85, 93] Haloplasmatales OrderDecrease[79] Verrucomicrobiota Roseibacillus GenusDecrease[88] Archaea‐Euryarchaeota Methanobrevibacter GenusIncrease[80, 93] Undefined AR31 Increase[79] Note: This table summarizes Mendelian randomization studies that have investigated causal relationships between gut microbiota and AD. For each microbial taxon, we have included its phylum classification, taxonomic rank, and reported association with AD risk (i.e., whether it increases or decreases the risk of AD). Causal relationships between gut microbiota and AD in Mendelian randomization studies. Note: This table summarizes Mendelian randomization studies that have investigated causal relationships between gut microbiota and AD. For each microbial taxon, we have included its phylum classification, taxonomic rank, and reported association with AD risk (i.e., whether it increases or decreases the risk of AD). Gut‐Brain Signaling Pathways Gut dysbiosis is increasingly recognized as a contributing factor in AD pathogenesis. The gut‐brain signaling network involves multiple interacting mechanisms that collectively link microbial imbalance to neurodegeneration (Table 2). Dysbiosis can compromise intestinal barrier integrity, facilitating the translocation of microbial products into systemic circulation [101]. These microbial signals, including both bioactive metabolites and structural components, influence neural function through distinct routes. TABLE 2Effects of gut microbial taxa on Alzheimer's disease pathology in experimental studies.No.Study typeStudy subjectsGut micro‐organismPhylumEffect on ADMechanismRef.Year1Animal studyAPP/PS1‐21 mice Bacteroides fragilis Bacteroidota DetrimentalSuppresses microglial phagocytic function → impaired Aβ clearance → Aβ plaque accumulation[36]20242Animal studyThy1‐human C/EBPβ transgenic mouse; AD patient FMT Bacteroides fragilis Bacteroidota Detrimental B. fragilis and its PUFA metabolites (12‐HHTrE, PGE2) activate microglia → upregulate C/EBPβ/AEP pathway → induce AD pathologies[37]20233Animal study5xFAD mouse Bacteroides ovatus Bacteroidota Protective B. ovatus hydrolyzes PC to LPC via PLA2; LPC activates GPR119 → upregulates NRF2 → inhibits ACSL4 expression → suppresses ferroptosis → reduces Aβ plaques, rescues synaptic function, decreases gliosis, ameliorates myelin degeneration[100]20254Animal studyGerm‐free 3 × Tg mice; AD patient FMT Bacteroides intestinalis , B. fragilis , B. xylanisolvens Bacteroidota DetrimentalActivates C/EBPβ/AEP pathway → upregulates PUFA metabolites and oxidative enzymes → microglia activation and neuroinflammation → exacerbates Aβ plaques, neurofibrillary tangles, and cognitive dysfunctions[38]20225Animal study Caenorhabditis elegans Bacteroides rodentium Bacteroidota DetrimentalIncreases Aβ plaques; suppresses p38‐MAPK activation; exacerbates paralysis[51]20256Animal study5xFAD transgenic AD mouse Clostridium sporogenes + xylan (synbiotic) Firmicutes ProtectiveSynbiotic ( C. sporogenes + xylan) enhances tryptophan metabolism → increases IPA production and IPA‐synthesizing bacteria (Lachnospira, Clostridium) → restores synaptic ultrastructure, suppresses neuroinflammation, reduces Aβ deposition in cortex and hippocampus, maintains gut barrier integrity[49]20247Animal study + Cell experimentAPP/PS1 mice; microglial cells Clostridium butyricum Firmicutes ProtectiveIncreases acetate‐producing bacteria and SCFAs; upregulates tight junction proteins (Claudin‐1, ZO‐1, Occludin) to restore intestinal barrier and reduce serum LPS; suppresses neuroinflammation (IL‐6, TNF‐α, IL‐1β) in brain; regulates JNK/CDK5/GSK‐3β pathway to inhibit Tau hyperphosphorylation; reduces neuronal apoptosis (Bax/Bcl‐2); acetate inhibits JAK/STAT3 signaling in microglia, reducing Aβ and p‐Tau[50]20258Animal study Caenorhabditis elegans Limosilactobacillus reuteri Firmicutes ProtectiveReduces Aβ plaque burden in head region; activates p38‐MAPK pathway (upregulates Tol‐1, Pmk‐1, Skn‐1); reduces paralysis rate[51]20259Animal study5xFAD mice Lactobacillus suilingensis + inulin (synbiotic) Firmicutes ProtectiveSynbiotic enhances tryptophan metabolism → increases ILA biosynthesis → ILA activates AhR signaling pathway in the brain → inhibits neuroinflammation → reduces Aβ accumulation and alleviates cognitive impairment[52]202510Animal study + Cell experiment5xFAD mice; cell culture with aryl hydrocarbon receptor (AhR) inhibitor Lactobacillus reuteri Firmicutes ProtectiveILA activates AhR signaling in the brain → activates microglia and astrocytes → reduces soluble Aβ levels → prevents Aβ accumulation and cognitive impairment[53]202411Animal study + Cell experimentMale adult MAPT P301S transgenic mice; Neuro‐2a/HEK‐293 T cells Blautia coccoides Firmicutes DetrimentalProduces TMAO; TMAO directly binds HIF1α → inhibits HIF1α signaling (HIF1α, HO‐1, SOD2, GPX4↓) → promotes oxidative stress (ROS↑) → promotes Tau phosphorylation (p‐Tau181, p‐Tau396↑) → exacerbates cognitive impairment[61]202512Animal study + Cell experiment5xFAD transgenic mice; human intestinal epithelial cells (HT29) Lactobacillus murinus Firmicutes Detrimental L.m. adheres to gut epithelia → increases lactate production → lactate activates GPR81‐NFκB axis in epithelial cells → stimulates SAA production → activates monocytes/DCs → promotes peripheral Th1 inflammation → exacerbates AD pathology[62]202413Animal studyMale C57BL/6 mice Lacticaseibacillus casei Firmicutes ProtectiveModulates Akt/CREB/BDNF signaling pathway → reduces Aβ aggregation, inhibits Tau hyperphosphorylation, prevents neuronal death → improves cognitive dysfunction[54]202214Animal studyD‐galactose/AlCl3 induced AD rats Lactobacillus plantarum MA2 Firmicutes Protective MA2 alleviates intestinal mucosal impairment → inhibits microglial activation via TLR4/MYD88/NLRP3 signaling pathway → MA2 reduces neuroinflammation and Aβ accumulation → improves cognitive deficits; MA2‐derived EPS directly inhibit Aβ42 aggregation and amyloid‐induced cytotoxicity[55]202215Animal studyD‐galactose and AlCl3‐induced AD model mice Lactiplantibacillus plantarum Firmicutes ProtectiveRegulates PI3K/Akt/GSK‐3β pathway → inhibits Tau hyperphosphorylation; increases serotonin, dopamine, and GABA levels; ameliorates neuronal damage, Aβ deposition, and Tau pathology; modulates gut microbial communities → improves cognitive function[56]202216Animal studyAPP transgenic mice Lactiplantibacillus plantarum LAB12 and Lacticaseibacillus casei Shirota Firmicutes ProtectiveDownregulates BACE1 mRNA expression; increases glutathione; reduces nitric oxide; improves memory[57]202317Animal studyMale APP/PS1 mice Limosilactobacillus mucosae Firmicutes ProtectiveActivates CB2 → upregulates Nrf2/HO‐1 antioxidant pathway → increases SOD2 and GPX4 → reduces oxidative stress → decreases Aβ deposition, Tau phosphorylation, neuronal damage, and cognitive impairment[58]202618Animal studyC57BL/6 J male mice and 3 × Tg‐AD mice Lactobacillus plantarum PS128 Firmicutes ProtectiveRegulates propionic acid levels and GSK3β activity; reduces Aβ deposition, BACE1 expression, Tau phosphorylation, gliosis, and neuronal loss; improves cognitive function[59]202119Animal study Drosophila melanogaster Enterobacteria Proteobacteria DetrimentalImmune hemocyte recruitment to the brain, triggering TNF‐JNK mediated neurodegeneration and oxidative stress[64]201720Animal study5xFAD mouse Escherichia coli Proteobacteria Detrimental E. coli colonization → MHCII antigen presentation in brain myeloid cells → promotes CD8+ T cell infiltration, suppresses the transition of microglia to a DAM, increases insoluble Aβ deposition → exacerbated cognitive decline[65]202521Animal studyWild‐type C57BL/6J, AppNL‐G‐F mice Helicobacter pylori (gastric pathogen) Proteobacteria Detrimental H. pylori OMVs cross biological barriers and reach the brain; taken up by astrocytes → C3‐C3aR signaling activation → glial cell activation and neuronal dysfunction → exacerbates Aβ pathology and cognitive decline[69]202322Cell experimentAGS cells; LN229 astrocytoma cells; neuronal and neuron‐astrocyte co‐culture Helicobacter pylori (conditioned media from clinical isolates) Proteobacteria Detrimental H. pylori conditioned media activates STAT1/STAT3 signaling → APP and APOE4 expression↑ → ROS↑ → astrogliosis (GFAP↑); STAT3 inhibition reduces pSTAT3 and AD marker expression[66]202423Animal studyC57BL/6J and APP/PS1 mice Escherichia coli Nissle 1917 Proteobacteria Protective EcN OMVs containing OmpA translocate to brain → suppress glial hyperactivation, reduce neuroinflammation, restore synaptic function (dendritic spine density↑), increase neuronal survival → reduce Aβ deposition and cognitive deficits; effects mediated via humoral (circulatory) and vagal pathways[72]202624Animal studyC57BL/6 mice Escherichia fergusonii (isolated from MCI patients) Proteobacteria DetrimentalMCI‐derived E. fergusonii induces TNF‐α expression in intestinal epithelial cells → LPS/TLR4/NF‐κB‐mediated neuroinflammation → cognitive impairment[67]202425Animal study3xTg‐AD Transgenic Mice Klebsiella pneumoniae Proteobacteria DetrimentalAntibiotic‐induced dysbiosis promotes K. pneumoniae translocation across gut epithelial barrier → bloodstream → crosses BBB → brain infection → neuroinflammation → total tau↑ in brain → neurobehavioral impairment[68]2024 Note: This table summarizes the effects of specific gut microbial taxa on AD pathology and cognitive function, as reported in experimental studies.Abbreviations: 12‐HHTrE, 12‐hydroxyheptadecatrienoic acid; ACSL4, acyl‐CoA synthetase long‐chain family member 4; AEP, asparagine endopeptidase; AhR, aryl hydrocarbon receptor; Akt, protein kinase B; APOE4, apolipoprotein E4; APP, amyloid precursor protein; Aβ, amyloid‐beta; BACE1, beta‐site APP cleaving enzyme 1; Bax, Bcl‐2‐associated X protein; BBB, blood–brain barrier; Bcl‐2, B‐cell lymphoma 2; BDNF, brain‐derived neurotrophic factor; C/EBPβ, CCAAT/enhancer‐binding protein beta; C3‐C3aR, complement component 3–C3a receptor; CB2, cannabinoid receptor type 2; CD, cluster of differentiation; CDK5, cyclin‐dependent kinase 5; CREB, cAMP response element‐binding protein; DAM, disease‐associated microglia; DC, dendritic cell; EPS, exopolysaccharide; FMT, fecal microbiota transplantation; GABA, gamma‐aminobutyric acid; GFAP, glial fibrillary acidic protein; GPR119, G protein‐coupled receptor 119; GPR81, G protein‐coupled receptor 81; GPX4, glutathione peroxidase 4; GSK‐3β, glycogen synthase kinase 3 beta; HIF1α, hypoxia‐inducible factor 1‐alpha; HO‐1, heme oxygenase 1; IL, interleukin; ILA, indole‐3‐lactic acid; IPA, indole‐3‐propionic acid; JAK/STAT3, Janus kinase/signal transducer and activator of transcription 3; JNK, c‐Jun N‐terminal kinase; LPC, lysophosphatidylcholine; MHCII, major histocompatibility complex class II; MYD88, myeloid differentiation primary response 88; NF‐κB, nuclear factor kappa B; NLRP3, NLR family pyrin domain containing 3; NRF2, nuclear factor erythroid 2‐related factor 2; OmpA, outer membrane protein A; OMV, outer membrane vesicle; PC, phosphatidylcholine; PGE2, prostaglandin E2; PI3K, phosphoinositide 3‐kinase; PLA2, phospholipase A2; p‐Tau, phosphorylated tau; PUFA, polyunsaturated fatty acid; ROS, reactive oxygen species; SAA, serum amyloid A; SCFA, short‐chain fatty acid; SOD2, superoxide dismutase 2; STAT, signal transducer and activator of transcription; Th1, T helper 1; TLR4, Toll‐like receptor 4; TMAO, trimethylamine N‐oxide; TNF, tumor necrosis factor. Effects of gut microbial taxa on Alzheimer's disease pathology in experimental studies. Note: This table summarizes the effects of specific gut microbial taxa on AD pathology and cognitive function, as reported in experimental studies. Abbreviations: 12‐HHTrE, 12‐hydroxyheptadecatrienoic acid; ACSL4, acyl‐CoA synthetase long‐chain family member 4; AEP, asparagine endopeptidase; AhR, aryl hydrocarbon receptor; Akt, protein kinase B; APOE4, apolipoprotein E4; APP, amyloid precursor protein; Aβ, amyloid‐beta; BACE1, beta‐site APP cleaving enzyme 1; Bax, Bcl‐2‐associated X protein; BBB, blood–brain barrier; Bcl‐2, B‐cell lymphoma 2; BDNF, brain‐derived neurotrophic factor; C/EBPβ, CCAAT/enhancer‐binding protein beta; C3‐C3aR, complement component 3–C3a receptor; CB2, cannabinoid receptor type 2; CD, cluster of differentiation; CDK5, cyclin‐dependent kinase 5; CREB, cAMP response element‐binding protein; DAM, disease‐associated microglia; DC, dendritic cell; EPS, exopolysaccharide; FMT, fecal microbiota transplantation; GABA, gamma‐aminobutyric acid; GFAP, glial fibrillary acidic protein; GPR119, G protein‐coupled receptor 119; GPR81, G protein‐coupled receptor 81; GPX4, glutathione peroxidase 4; GSK‐3β, glycogen synthase kinase 3 beta; HIF1α, hypoxia‐inducible factor 1‐alpha; HO‐1, heme oxygenase 1; IL, interleukin; ILA, indole‐3‐lactic acid; IPA, indole‐3‐propionic acid; JAK/STAT3, Janus kinase/signal transducer and activator of transcription 3; JNK, c‐Jun N‐terminal kinase; LPC, lysophosphatidylcholine; MHCII, major histocompatibility complex class II; MYD88, myeloid differentiation primary response 88; NF‐κB, nuclear factor kappa B; NLRP3, NLR family pyrin domain containing 3; NRF2, nuclear factor erythroid 2‐related factor 2; OmpA, outer membrane protein A; OMV, outer membrane vesicle; PC, phosphatidylcholine; PGE2, prostaglandin E2; PI3K, phosphoinositide 3‐kinase; PLA2, phospholipase A2; p‐Tau, phosphorylated tau; PUFA, polyunsaturated fatty acid; ROS, reactive oxygen species; SAA, serum amyloid A; SCFA, short‐chain fatty acid; SOD2, superoxide dismutase 2; STAT, signal transducer and activator of transcription; Th1, T helper 1; TLR4, Toll‐like receptor 4; TMAO, trimethylamine N‐oxide; TNF, tumor necrosis factor. Based on the routes through which these signals reach the central nervous system, gut‐brain communication can be broadly divided into three interconnected axes: chemical/metabolic pathways, immune‐mediated pathways, and neural pathways (Figure 1). Schematic illustration of gut‐brain signaling pathways in AD pathogenesis. Gut dysbiosis compromises intestinal barrier integrity, allowing microbial signals to reach the brain through three interconnected axes. Chemical/metabolic pathways involve microbial metabolites and neurotransmitters that enter the peripheral circulation, cross the BBB, and modulate neurodegenerative processes via specific receptors. Immune‐mediated pathways are driven by microbial structural components that activate peripheral immune cells and trigger systemic inflammation, promoting peripheral immune infiltration and microglial activation. Neural pathways operate through the vagus nerve and the HPA axis. Collectively, these three axes converge to drive neuroinflammation, Aβ deposition, tau phosphorylation, oxidative stress, mitochondrial dysfunction, and synaptic impairment, culminating in AD pathology. 5‐HT, 5‐hydroxytryptamine; AD, Alzheimer's disease; AhR, aryl hydrocarbon receptor; Aβ, amyloid‐β; BBB, blood–brain barrier; GABA, gamma‐aminobutyric acid; HPA axis, hypothalamic–pituitary–adrenal axis; IL, interleukin; LPS, lipopolysaccharide; MCP‐1, monocyte chemoattractant protein‐1; OMVs, outer membrane vesicles; PUFAs, polyunsaturated fatty acids; ROS, reactive oxygen species; SCFAs, short‐chain fatty acids; TMAO, trimethylamine N‐oxide; TNF‐α, tumor necrosis factor‐alpha. Chemical/Metabolic Pathways Microbial metabolites represent the most direct signaling arm of the gut‐brain axis. SCFAs, tryptophan derivatives (including IPA and ILA), and other bioactive molecules enter the portal circulation and may reach the brain directly or influence host metabolism at peripheral sites [102, 103]. The gut microbiota also influences neurotransmitter systems, modulating the production of serotonin, GABA, and dopamine that can affect brain function through the gut‐brain axis [104]. Metabolites exert divergent effects. Some support microglial homeostasis, maintain BBB integrity, and suppress neuroinflammation through receptors such as AhR [105]. Others, including TMAO and certain PUFA metabolites, promote oxidative stress, tau phosphorylation, or inflammatory cascades [38, 61]. The net effect on the brain depends on the compositional and functional configuration of the microbial community. Immune‐Mediated Pathways Along with the bioactive molecules mentioned above, structural components such as LPS and OMVs activate peripheral immune cells upon entering the circulation, triggering systemic inflammation [67, 69]. This peripheral inflammation can compromise BBB integrity, facilitating the entry of inflammatory mediators and immune cells into the brain [106]. Within the central nervous system, microglial activation and peripheral immune infiltration amplify neuroinflammation. Conversely, certain microbial signals can also suppress inflammatory responses and maintain immune homeostasis, indicating that the immune axis is bidirectional. Neural Pathways The vagus nerve serves as a direct anatomical conduit between the gut and the brain [107, 108]. Vagal afferent fibers in the intestinal mucosa can detect chemical and mechanical signals from the gastrointestinal tract, and their activity is modulated by various hormonal signals [109]. These signals are transmitted to the brainstem and then to higher brain regions. Beyond the vagus nerve, neuroendocrine regulation also contributes to gut‐brain communication. The hypothalamic–pituitary–adrenal (HPA) axis integrates stress and metabolic signals, and its dysregulation has been linked to neuroinflammation in AD [110]. The vagus nerve can also mediate anti‐inflammatory effects through the cholinergic reflex, providing a rapid communication route that complements slower humoral and metabolic signaling [111]. Integration and Crosstalk The three signaling axes do not operate in isolation, but form a highly integrated network [112]. Barrier disruption amplifies immune activation. Metabolic signals can modulate neural excitability. Neuroinflammation can in turn compromise both intestinal and BBB integrity. This interconnectivity has therapeutic implications. Interventions targeting a single axis may elicit compensatory responses along the others, whereas strategies that concurrently modulate multiple pathways may offer synergistic benefits. Collectively, these findings establish the gut‐brain axis as a multidirectional signaling network through which gut dysbiosis may influence AD pathogenesis. This framework provides a mechanistic basis for the nutritional and metabolic interventions discussed in subsequent sections [113]. Single Nutrient, Metabolites, and AD Dietary nutrients and gut microbial metabolites represent two interconnected yet distinct categories of factors that influence AD through the gut‐brain axis. This section begins with three classes of dietary nutrients with established neuroprotective properties, namely N‐3 polyunsaturated fatty acids (N‐3 PUFA), polyphenols, and vitamins, which exert direct effects on brain health. Amino acids are then addressed as a key example of this intermediate category, functioning as both dietary constituents and metabolic substrates for gut microbiota and neurotransmitter synthesis, thereby linking nutrient intake to microbial metabolism. The section concludes with two major classes of gut microbial metabolites, short‐chain fatty acids (SCFAs) and trimethylamine‐N‐oxide (TMAO), illustrating how the gut microbiota transduces dietary components into bioactive signals that modulate AD pathogenesis. This progression from nutrients to metabolites provides a conceptual framework for understanding the continuum of diet‐microbiome‐brain interactions in AD (Figure 2). Schematic overview of the gut‐brain axis in AD. Dietary components (foods and single nutrients, e.g., vitamins, amino acids, PUFAs) modulate gut microbiota composition. Microbial metabolism, including fermentation and biotransformation, generates bioactive metabolites (e.g., SCFAs, TMAO, polyphenol derivatives) that regulate intestinal barrier function and immune responses. These gut‐derived signals influence brain pathology through neuroinflammation, barrier integrity, neurotransmitter signaling, and proteinopathy (Aβ aggregation, Tau phosphorylation). N‐3 Polyunsaturated Fatty Acids N‐3 PUFA, including eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA), possess anti‐inflammatory and neuroprotective properties. A 2012 systematic review and meta‐analysis of animal studies demonstrated that long‐term N‐3 PUFA supplementation reduced Aβ burden, improved cognitive performance, and attenuated neuronal loss in AD models [114]. Recent evidence suggests that gut microbiota composition may contribute to interindividual variability in the efficacy of N‐3 PUFA supplementation [115]. Direct evidence from AD mouse models indicates that dietary N‐3 PUFA interventions modulate gut microbiota composition and inflammation. In APP/PS1 mice, EPA supplementation increased butyrate‐producing Firmicutes, reduced Gram‐negative Bacteroidetes, and concurrently downregulated MHCII+ microglia in the hippocampus and retina, without altering Aβ plaque burden or microglial phagocytosis [116]. Similarly, supplementation with medium‐chain triglycerides (MCTs) combined with DHA in APP/PS1 and SAMP8 mice decreased the relative abundance of Proteobacteria and the Firmicutes/Bacteroidetes ratio, accompanied by reduced serum pro‐inflammatory cytokines (IL‐2, IL‐6, MCP‐1, TNF‐α) and elevated anti‐inflammatory IL‐10 [117]. In 5 × FAD mice, DHA‐enriched egg yolk lipid supplementation increased AD‐beneficial genera including Muribaculaceae and Lachnospiraceae and suppressed microglial activation‐induced neuroinflammation [118]. A high ω‐6/ω‐3 diet (low ω‐3) significantly altered gut microbial diversity and increased genera associated with AD and inflammation in APP/PS1 mice, suggesting that low ω‐3 levels may exacerbate neuropathology through gut microbiota reorganization [119]. The causal involvement of the gut microbiota was further examined through FMT. Transfer of gut microbiota from N‐3 PUFA‐fed donors into recipient diabetes‐associated cognitive dysfunction rats recapitulated the improvements in cognitive function, neuroinflammation, and synaptic protein expression [120]. Collectively, these findings indicate that N‐3 PUFA, particularly EPA and DHA, may influence AD‐related pathology through gut microbiota modulation and attenuation of neuroinflammation, highlighting the potential of dietary N‐3 PUFA supplementation as a non‐invasive strategy to support cognitive health in the context of AD. Polyphenols Polyphenols are plant‐derived compounds characterized by phenolic rings and are abundant in fruits, vegetables, and whole grains [121]. They have been shown to reduce Aβ production, prevent Aβ aggregation, and diminish oligomer cytotoxicity [122], and mechanistic studies have further demonstrated their ability to inhibit tau hyperphosphorylation and suppress tau β‐sheet formation [123]. However, translation of these preclinical findings into clinical efficacy remains challenging due to poor bioavailability and BBB permeability [122]. Beyond these direct actions on amyloid and tau pathologies, emerging evidence suggests that polyphenols may exert neuroprotective effects through modulation of the gut–brain axis [124]. In vitro studies have shown that phenolic compounds selectively promote the growth of probiotic lactobacilli while inhibiting pathogenic bacteria [125], and polyphenols and their metabolites have been reported to enhance intestinal barrier integrity [126]. In naturally aged mice, a blueberry‐mulberry extract improved spatial memory, reduced hippocampal neuronal loss and brain IL‐6 and TNF‐α while increasing IL‐10, and altered gut microbiota by increasing Lactobacillus, Streptococcus, and Lactococcus while decreasing Blautia, Lachnoclostridium, and Roseburia [127]. Similarly, in D‐galactose‐induced aging mice, whole fruit phenols from kumquat reduced oxidative stress, lowered hippocampal inflammatory markers and acetylcholinesterase activity, increased acetylcholine levels, modulated gut microbiota by enriching beneficial bacteria and reducing Bacteroides and Escherichia‐Shigella, and enhanced intestinal barrier function [128]. In 5xFAD and APP/PS1 transgenic mice, Triphala improved cognitive function, modulated the APP pathway, reduced inflammation, and increased Bacteroides, Proteobacteria, and Actinobacteria [129]. In 3xTg‐AD mice fed a high‐fat high‐sugar diet, curcumin improved spatial working memory, accompanied by enrichment of Oscillospiraceae and Rikenellaceae at the family level and Oscillibacter, Alistipes, Pseudoflavonifractor, Duncaniella, and Flintibacter at the genus level. Transcriptomic analysis of the hippocampus revealed that curcumin modulated pathways related to synaptic plasticity, excitatory postsynaptic potential, and mitochondrial organization [130]. The causal involvement of gut microbiota in mediating these effects was further supported by a FMT experiment, in which transfer of microbiota from Phyllanthus emblica polyphenol‐treated donors into recipient mice alleviated cognitive impairment and neuroinflammation [131]. Collectively, these findings suggest that dietary polyphenols may represent a viable nutritional strategy for AD prevention, acting through both direct anti‐amyloid and anti‐tau effects and indirect modulation of the gut‐brain axis. Vitamins Vitamins are essential micronutrients categorized into fat‐soluble (A, D, E, K) and water‐soluble (B‐complex, C) groups. Epidemiological evidence has linked inadequate vitamin status to cognitive decline and increased risk of AD. Low serum vitamin D is associated with poorer neuroimaging outcomes and incident dementia [132]. This association has been confirmed by a meta‐analysis of prospective studies [133] and also supported by Mendelian randomization evidence for a causal role [134]. Vitamin E has been implicated in AD through its antioxidative and anti‐inflammatory properties [135], and emerging evidence also suggests that gut microbiota modulation may represent a potential mechanism for delaying AD progression [136]. The gut microbiota plays a bidirectional role in vitamin metabolism. Gut bacteria can synthesize certain vitamins, while vitamins in turn influence microbial composition and function [137]. Vitamin A, via its active metabolite all‐trans retinoic acid (ATRA), maintains intestinal epithelial integrity by upregulating tight junction proteins [138]. In APP/PS1 mice, vitamin A deficiency increased intestinal permeability, elevated inflammatory cytokines, exacerbated Aβ pathology, and induced gut microbiota dysbiosis and cognitive deficits, while vitamin A supplementation attenuated these pathological changes [139, 140]. Folate and vitamin B12 deficiency link to increased risk of cognitive impairment [141]. In Aβ‐infused rats, combined deficiency additively impaired memory function and disturbed gut microbiota composition [142]. Interestingly, univariate Mendelian randomization found no significant direct associations between vitamin B supplementation and AD risk. However, mediation analysis revealed that Lachnospiraceae, Defluviitaleaceae, and Bifidobacterium fully mediated the relationships between B12, B6, and B complex supplementation, respectively, and AD risk [91], highlighting the potential role of gut microbiota in mediating the effects of B vitamins on AD risk. Vitamin C mitigated cognitive impairment in D‐galactose‐induced aging mice, accompanied by increased microbial diversity, particularly the enrichment of SCFA‐producing genera [143]. Collectively, these findings indicate that vitamins may influence AD pathogenesis through gut microbiota modulation, oxidative stress reduction, and systemic inflammation, underscoring the potential for personalized nutritional strategies targeting the gut‐brain axis. Amino Acids and Their Metabolites Amino acids are the building blocks of proteins and serve as precursors for neurotransmitters, microbial metabolites, and energy metabolism. A prospective cohort study suggested that lower circulating levels of essential amino acids, particularly branched‐chain amino acids, are associated with a reduced risk of AD [144]. Animal studies have further shown that dietary supplementation with essential amino acids can attenuate neuropathology and inflammation in AD‐related models [145, 146]. Beyond serving as direct nutrients, amino acids also function as key metabolic mediators linking gut microbiota dysbiosis to AD pathology. During AD progression, gut microbiota dysbiosis causes an abnormal elevation of phenylalanine and isoleucine, which promote Th1 cell infiltration into the brain, contributing to M1 microglial activation and neuroinflammation [147]. Among amino acids, tryptophan metabolism is a central pathway in microbiota‐gut‐brain communication. Tryptophan is metabolized along three principal routes: the kynurenine pathway, the serotonin pathway, and the indole pathway [148]. The kynurenine pathway produces metabolites such as kynurenine and quinolinic acid that are implicated in neuroinflammation and excitotoxicity. In parallel, the indole pathway generates metabolites that activate the aryl hydrocarbon receptor (AhR), a ligand‐activated transcription factor enriched in brain microvessels [149]. Of note, AhR activation exerts context‐dependent effects in AD. On one hand, AhR signaling has been associated with BBB disruption and neuroinflammation [150]. On the other, AhR activation by indole‐3‐acetic acid (IAA) has been linked to neuroprotective outcomes, with IAA levels positively correlating with cognitive performance. In APP/PS1 mice, Akkermansia muciniphila administration increased serum IAA and tryptophan levels and activated the AhR/NF‐κB/NLRP3 pathway, reducing Aβ deposition and neuroinflammation [151]. Other amino acids have also been implicated in AD through microbiota‐dependent mechanisms. In a white matter injury model, reduced L‐arginine was associated with cognitive decline. Lachnospiraceae were identified as a primary source of gut‐derived L‐arginine, and supplementation with either L‐arginine or Lachnospiraceae alleviated the decline [152]. Dietary methionine restriction improved cognition in APP/PS1 mice through gut microbiota‐dependent mechanisms and inflammation‐related mechanisms, involving modulation of tryptophan metabolism [153], SCFA signaling [154], and suppression of astrocyte‐mediated neuroinflammation via the TGF‐β1/CCN2/NF‐κB pathway [155]. Furthermore, high methionine intake was reported to impair cognition in non‐transgenic mice [156]. Isoleucine restriction also improved cognitive function in high‐fat diet‐induced obese mice through the gut‐brain axis [157]. Collectively, these findings indicate that amino acids act as both essential nutrients and metabolic intermediates through which gut microbiota influences AD pathogenesis, suggesting that targeting amino acid metabolism through dietary or microbiota‐directed strategies may offer a viable approach for gut‐brain axis‐based intervention. Short‐Chain Fatty Acids SCFAs, primarily including acetate, propionate, butyrate, isobutyrate, valerate, and isovalerate, are produced by gut microbiota through dietary fiber fermentation [158]. Multiple lines of evidence have observed alterations in gut microbial composition and SCFA profiles in AD patients and at‐risk populations. For instance, SCFA‐producing families Lachnospiraceae and Bacteroidaceae, genus Ruminococcus (phylum Firmicutes) were significantly reduced in AD patients [45]. Similarly, an Anaerostipes‐enriched enterosignature (ES‐Ana) positively associated with butyrate biosynthesis decreased progressively from healthy controls to AD patients and correlated positively with cognitive scores [159]. In cognitively unimpaired adults, higher cerebral Aβ burden was associated with distinct gut microbial and SCFA profiles, suggesting that gut dysbiosis and SCFA alterations occur before symptom onset [160]. Additionally, fecal propionate, isovalerate, and propionate‐producing bacteria were inversely associated with amyloid status, with propionate mediating the link between gut microbes and AD biomarkers [161]. The protective effects of SCFAs against AD are supported by multiple mechanistic studies. In AD mouse models, butyrate increases hippocampal histone acetylation levels and upregulates the expression of genes related to associative learning, thereby restoring memory function [162]. Valerate, butyrate, and propionate disrupt toxic soluble Aβ aggregation [163]. Propionate and butyrate can inhibit LPS‐induced cytokines IL‐6 and IL‐12p40 expression in human mature dendritic cells [164], suggesting that SCFAs may attenuate neuroinflammation [165]. Of note, while butyrate exerts consistent protective effects against AD, propionate may be either beneficial or detrimental depending on the specific pathway involved [166]. Beyond direct effects, SCFAs also influence central nervous system function indirectly through the gut‐brain axis [167]. In the gut, they modulate intestinal pH [168], promote mucin secretion [169], regulate intestinal permeability [170], enhance gut immune barrier function [171], provide energy for colonocytes [172], and increase mineral absorption [173]. These local actions, together with direct effects on BBB integrity and glial cells, as well as modulation of immune and vagal pathways, enable SCFAs to impact neuronal homeostasis and AD pathogenesis [174, 175, 176]. Functional analysis further revealed that higher Aβ burden correlated with a shift from anabolic biosynthesis (synthesis of beneficial metabolites, e.g., L‐arginine biosynthesis) to fermentative pathways (a catabolic state linked to dysbiosis, e.g., pyruvate fermentation to acetone). This finding implies that restoring overall microbial functional homeostasis may be more critical than simply replenishing SCFA‐producing bacteria, supporting early intervention before symptom onset as a promising strategy to modify AD progression [177]. Trimethylamine‐N‐Oxide TMAO is a gut microbiota‐derived metabolite produced from dietary choline, betaine, and L‐carnitine [178], with final oxidation in the liver primarily by flavin monooxygenase 3 (FMO3) [179]. Dietary patterns influence gut‐derived TMAO levels: plant‐based diets associated with lower production [180], whereas long‐term high‐fat diets alter intestinal epithelial physiology, increase Enterobacteriaceae abundance, and enhance choline catabolism by Escherichia coli , thereby elevating circulating TMAO [181]. Multiple observational studies consistently report elevated TMAO levels in AD patients. Vogt et al. found that cerebrospinal fluid (CSF) TMAO levels were significantly higher in AD patients and correlated with biomarkers of AD pathology and neuronal degeneration [182]. Meta‐analyses have further confirmed the positive association between TMAO and cognitive impairment [183, 184]. Mechanistically, TMAO may induce cognitive dysfunction and brain aging via inhibition of the mTOR signaling pathway, leading to impaired synaptic plasticity [185]. A computational pathway analysis identified TMAO as the top‐ranked metabolite associated with AD biomarkers, revealing nine shared genetic pathways underlying both AD and TMAO metabolism [186]. Recent studies provide direct causal evidence linking specific gut microbes to AD via TMAO. Lv et al. found that Blautia coccoides (a species of Bacillota) abundance is increased in AD patients and predicts p‐Tau181 levels; supplementation with this bacterium exacerbated cognitive deficits and Tau pathology in AD mice via TMAO‐HIF1α signaling [61]. Zhang et al. showed that cognitive training reduced TMAO levels in AD patients, correlating with changes in Roseburia, Lactobacillus, and Ruminococcus; in APP/PS1 mice, TMAO supplementation impaired cognition, disrupted BBB, and increased Aβ deposition [187]. However, a bidirectional MR study found no significant causal association between genetically predicted TMAO and AD risk, nor for its precursor choline, betaine, or L‐carnitine; reverse analysis also found no causal effect of AD on TMAO levels [188]. Interestingly, another study found that TMAO may enhance BBB integrity and protect against inflammatory damage, whereas its precursor trimethylamine (TMA) exerts opposite effects [189]. These conflicting findings suggest that the role of TMAO in AD is complex and context‐dependent, warranting further investigation. Future studies integrating large population cohorts and mechanistic research are needed to clarify its exact role. Dietary Patterns and AD Diet is increasingly recognized as a comprehensive concept comprised of nutrients, foods, trace elements, macronutrients, and their complex interactions [190]. While most research on nutrition and AD risk has focused on individual nutrients, it often overlooks the complex interplay, the synergies and antagonisms, among different dietary components that fundamentally shape human diets [191]. Unhealthy dietary patterns, such as the Western diet, exemplify how such interactions can produce detrimental health outcomes. Studies show that Western diet‐induced metabolic syndrome initiates a pathogenic cascade from obesity, adipose tissue inflammation, and gut dysbiosis to exacerbated systemic inflammation, culminating in BBB damage, neuroinflammation, toxic amyloid accumulation, and finally, synaptic dysfunction, neurodegeneration, and cognitive impairment [192, 193]. Numerous animal and human studies have confirmed that high‐fat diets cause alterations in gut microbiota composition and diversity, such as a 50% reduction in bacterial abundance and an increased ratio of Firmicutes to Bacteroidetes [194, 195]. Moreover, recent evidence in mice fed an atherogenic high‐fat diet revealed that live bacteria can translocate from the gut to the brain via the vagus nerve, a phenomenon reversible upon return to normal diet [196]. Similarly, a fiber‐deficient diet, mimicking another feature of Western dietary patterns, induced cognitive impairment in mice, accompanied by hippocampal synaptic damage, microglial‐mediated synaptic engulfment, and reduced SCFA production. Gut microbiota changes were detectable as early as 7 days before cognitive decline [197]. Collectively, metabolic syndrome and gut microbiota dysbiosis, resulting from unhealthy dietary habits, are key drivers in the development of AD. Healthy dietary patterns play a positive role in preventing AD. Studies have found that the Mediterranean diet (MeDi), the Dietary Approaches to Stop Hypertension (DASH) diet, and the Mediterranean‐DASH Intervention for Neurodegenerative Delay (MIND) diet are associated with improved cognitive scores in individuals aged 40 and over [198, 199, 200]. The MeDi is characterized by high consumption of fruits, vegetables, legumes, and fish, includes healthy fats such as olive oil, and involves moderate intake of dairy products, meat, and saturated fatty acids [201]. The neuroprotective effects of the MeDi have been mechanistically linked to its polyphenol components, particularly resveratrol and oleuropein, which modulate oxidative stress, neuroinflammation, mitochondrial function, and the gut‐brain axis through pathways such as SIRT1 activation [202]. Long‐term MeDi intervention has been reported to drive beneficial gut microbiome alterations in non‐human primates, leading to the hypothesis that positive modulation of microbial diversity, composition and function acts as a key factor mediating the health benefits of the MeDi for the host [203]. Similar to the MeDi, the DASH diet also prescribes a high intake of plant‐based foods and additionally restricts the consumption of saturated fat and total fat [204]. The MIND diet integrates principles from the MeDi and DASH diets. It emphasizes intake of natural plant‐based foods, berries, and leafy greens, restricts animal‐based and high‐saturated‐fat foods, and this dietary pattern has been demonstrated to offer neuroprotective benefits [205]. In addition to these well‐established dietary patterns, the ketogenic diet (KD) has emerged as another potential strategy for neuroprotection in AD. In a transgenic AD mouse model, a modified Mediterranean‐KD promoted Lactobacillus growth and lactate production, which upregulated serum metabolites that attenuated neuroinflammatory pathways in the hippocampus [206]. In a human crossover trial involving prediabetic adults with MCI, a similar diet modulated the gut microbiome and metabolome in a cognitive status‐dependent manner, including reduced GABA‐producing Alistipes and increased Akkermansia muciniphila [207]. However, the effects of KD may depend on additional environmental factors. In a mouse model combining KD with intermittent hypoxia, gut microbiota alterations, particularly Bilophila expansion, disrupt hippocampal function and cognitive behavior via proinflammatory immune activation. Notably, microbiome depletion prevents this cognitive decline, underscoring the causal role of gut microbes in this context [208]. Intermittent fasting (IF), which primarily includes dietary rhythm interventions such as alternate‐day fasting (ADF), time‐restricted feeding (TRF), and periodic fasting (PF), has become a major focus in nutritional research for its potential to improve brain homeostasis [209]. Studies found that IF can promote the enrichment of probiotics like Lactobacillus, modulate gut microbiota composition and metabolite profiles, protect intestinal barrier integrity, inhibit cerebral Aβ deposition and neuroinflammation, improve synaptic structure, and ameliorate AD‐related cognitive function [210, 211, 212, 213, 214]. In summary, promoting healthy dietary patterns and dietary rhythms holds significant clinical importance for preventing or delaying the chronic, insidious progression of AD‐related cognitive impairment. Future Perspectives and Challenges Mendelian Randomization for Causal Inference Although MR studies have provided genetic evidence for a causal role of gut microbiota in AD (Section 3.4; Table 1), the direction of causal effects for certain taxa remains inconsistent across studies [95, 96]. These discrepancies may arise from differences in taxonomic resolution, GWAS data sources, AD outcome definitions (e.g., clinically diagnosed AD versus proxy cases, or cognitive performance metrics), and analytical methods [80, 215]. Future MR studies would benefit from standardized analytical pipelines, multi‐ancestry GWAS data, and more rigorous sensitivity analyses. Triangulating MR evidence with randomized controlled trials (RCTs) or animal experiments will also be essential to firmly establish causality. Beyond establishing causality, recent MR studies have directly demonstrated the existence of specific microbiota‐brain structure axes causally involved in AD mechanisms (e.g., Butyrivibrio‐brain stem‐AD) [80]. These findings provide genetic evidence supporting the gut‐brain axis as a mechanistic framework for AD, reinforcing the rationale for microbiome‐targeted nutritional interventions. Furthermore, mediation MR analyses have identified several blood metabolites (e.g., glutamine, alanine, indole‐3‐carboxylate, and other amino acid derivatives) [78, 81, 82], immune cell phenotypes (e.g., effector memory CD4+ T cells, CD45 on Mo MDSC) [83, 92], lipid‐related mediators [88], vitamin‐related pathways [91], hub genes [79, 94], and epigenetic modifiers [84] as potential mediators. Upstream nutritional factors, such as the trace elements copper and carotene, may also influence AD risk through gut microbiota mediation [216]. Collectively, these findings identify a set of gut microbiota‐related mediators that may serve both as biomarkers and as direct nutritional targets for AD intervention. Future research should therefore focus on: (1) moving beyond genus‐level associations to strain‐level and pathway‐specific causal inference using metagenomic GWAS; (2) integrating multi‐omics data (metabolomics, proteomics, immunomics, epigenomics) for network mediation analysis to identify additional mediators; (3) validating the functional relevance of MR‐identified mediators through in vitro and in vivo experiments; (4) translating these findings into precision nutrition strategies by using genetically supported mediators as biomarkers for patient stratification or as direct nutritional targets; and (5) exploring other trace elements and dietary components as upstream modulators of the gut microbiota‐AD axis. From Dietary Patterns to Precision Nutrition Dietary patterns such as the Medi, MIND, and KD exert neuroprotective effects at the population level [217]. However, individual responses vary considerably, influenced by genetic factors, gut microbiome composition, and metabolic phenotype [218]. The ApoE4 allele, the most well‐studied genetic risk factor for late‐onset AD, exemplifies this heterogeneity. ApoE4 carriers exhibit distinct alterations in microglial function, astrocyte lipid metabolism, BBB integrity, and insulin sensitivity, all of which may modulate their response to dietary interventions [219]. Preclinical evidence directly supports this notion. In APOE4‐targeted replacement mice, a KD induced genotype‐ and sex‐dependent gut microbiome and brain metabolic responses. The most pronounced benefits were observed in female APOE4 mice, whereas APOE3 mice exhibited only limited brain metabolic changes despite comparable microbiome alterations [220]. Theoretically, precision nutrition targeting metabolic pathways altered by ApoE4 could provide a tool for disease prevention. However, whether these preclinical findings translate to humans remains unclear, as long‐term clinical evidence specifically for ApoE4 carriers remains inconclusive [219]. Beyond genetic determinants, physiological responses also depend on sex, age, dietary habits, and baseline microbiome composition [221]. Precision nutrition is increasingly supported by multi‐omics technologies such as nutrigenomics, metabolomics, transcriptomics, and proteomics, which provide system‐level insights into individual metabolic responses [222]. Artificial intelligence (AI) further integrates multimodal data, including wearable biosensors, dietary tracking, and machine learning models, to generate personalized dietary recommendations [223, 224]. One ongoing clinical trial is using AI and network analysis to design personalized supplements for AD patients based on their microbiota, clinical, and dietary data, targeting disease‐associated microbial taxa and metabolic pathways [221]. Despite its promise, precision nutrition for AD prevention faces substantial hurdles. First, RCTs have failed to consistently support the protective effects observed in observational studies [225]. Second, integrating multi‐omics data and predicting individual responses remain major translational barriers [218], while AI‐driven tools face additional challenges in validation, generalizability, and ethical implementation [223]. Third, practical constraints complicate implementation. AD patients often struggle with dietary adherence, placing the burden on informal caregivers [226]. Finally, regulatory frameworks remain fragmented, as microbiome‐based products are classified variably as foods, supplements, or drugs across jurisdictions, creating inconsistencies in approval, labeling, and safety requirements [227]. Collectively, these findings suggest that transitioning from population‐level to genotype‐ and microbiome‐informed precision nutrition is a logical next step in AD prevention research. However, this transition requires rigorous validation through longitudinal human studies, standardized multi‐omics methodologies, accounting for individual variability [218, 223]. Microbiome‐informed precision medicine holds potential, yet substantial gaps remain in understanding gut microbiota‐immune‐brain interactions [228]. Addressing these gaps will require biomarker discovery, large‐scale trials, and clinical practice frameworks. FMT and Next‐Generation Microbiome‐Based Therapies Fecal microbiota transplantation (FMT) is a therapeutic procedure that transfers fecal microbiota from healthy donors to recipients. Animal studies have established FMT as a proof‐of‐concept intervention for AD. FMT remodels gut microbial composition, restores SCFAs levels, reduces neuroinflammation, and attenuates Aβ and tau pathologies, leading to cognitive improvement in transgenic mouse models [229, 230]. Mechanistically, FMT suppresses the TREM2/SYK/NF‐κB pathway in APP/PS1 mice, reducing hippocampal neuroinflammation and synaptic protein loss and reversing M1‐associated microglial polarization [231]. The efficacy of FMT depends on donor characteristics, administration protocol, and host factors. In 5xFAD mice, transplantation of cecal material from older donors increased plaque burden in the prefrontal cortex and dentate gyrus compared with material from young donors [232]. FMT from a human donor carrying the protective APOE2 allele improved short‐term recognition memory in 3xTgAD mice compared with FMT from an AD patient donor [233]. Dosage and frequency of transplantation also critically determine FMT efficacy. Every‐other‐day FMT intervention significantly improved AD pathology and symptoms, while weekly administrations failed to produce comparable improvements and cognitive benefits. Moreover, the protective effects of FMT on cognitive function were not sustained beyond 4 weeks post‐FMT cessation, elucidating the time‐effectiveness characteristics of FMT [234]. In a traumatic brain injury model, females showed less microglial suppression and distinct microglial remodeling in response to FMT compared with males, which may be attributed to sex‐specific differences in sex hormones, immune signaling pathways, and microbiota composition [235]. Despite the promise shown in animal studies, clinical translation of FMT for AD faces substantial hurdles. Available human evidence is restricted to a few case reports and small case series, with no large‐scale RCTs to date [236]. A pilot single‐arm trial in five patients with cognitive impairment demonstrated that FMT capsules were well tolerated with no adverse events. Cognitive scores improved or stabilized over 6 months in MCI cases, while severe dementia patients remained stable [237]. Two case reports of AD patients receiving FMT for recurrent Clostridioides difficile infection (CDI) noted cognitive gains, with MMSE scores improving from 20 to 26 at 2 months and to 29 at 6 months in an 82‐year‐old patient [238], and similar improvement in a 90‐year‐old patient after two FMT infusions [239]. While these observations are encouraging, clinical exploration of FMT as a dedicated treatment for AD remains limited [240]. Several factors contribute to the translational gap. First, the mechanisms linking gut microbiota to cognitive function are not fully understood [227]. Second, substantial interspecies differences in gut microbiota between rodents and humans, along with the challenges in selecting optimal transplant donors, pose significant obstacles [241]. Third, FMT carries risks including gastrointestinal adverse events, pathogen transmission, and potential long‐term consequences such as weight gain and metabolic changes [241]. Fourth, regulatory frameworks for FMT remain challenging. In the United States, FMT is regulated as an investigational drug, requiring an Investigational New Drug application for most uses, with FDA enforcement discretion limited to recurrent CDI unresponsive to standard treatments. FMT's classification as a live biotherapeutic product demands thorough characterization and compositional consistency; however, requirements are currently infeasible for complex fecal preparations [242]. Standardization of FMT protocols for AD patients, including donor screening, processing methods, quality control, and optimal dosing strategies, also remains a critical unmet need [243]. To address some limitations of conventional FMT, next‐generation microbiome‐based therapies are emerging [244]. Phage therapy offers a strategy to selectively eliminate pathogenic bacteria [245]. The gut virome changes with aging, and phage‐bacteriome‐metabolome interactions show distinct patterns linked to cognitive dysfunction in older adults [246]. An intermediate approach in terms of microbial complexity between whole‐stool FMT and single‐strain probiotics has also been explored. A defined consortium of eight dominant murine gut bacterial species restored gut microbial composition, reduced neuroinflammation, and Aβ plaque deposition in APP/PS1 mice, with effects superior to a single Enterococcus strain [247]. Beyond naturally occurring consortia, synthetic microbial communities (SynComs), composed of defined and reproducible bacterial strains, have emerged as reductionist models to dissect causal relationships between specific microbial taxa and neuroinflammation in AD, though their direct therapeutic application remains to be established [248]. Engineered bacteria represent another frontier [244]. A strain of engineered butyrate‐producing Saccharomyces cerevisiae (J17) rescued butyrate deficiency in AD mice and reduced Aβ plaque burden, microglia activation, and neuroinflammation [249]. Compared with FMT, which contains unknown or conditional pathogens, these approaches offer the advantage of defined composition and more predictable safety profiles [250]. However, these next‐generation therapies remain in early preclinical stages and require further validation of their dosage effects and long‐term safety. Conclusions In this review, we aim to systematically synthesize current evidence on how nutritional and metabolic factors modulate the gut‐microbiota‐brain axis and exert therapeutic effects in AD, integrating findings from observational studies, interventional trials, animal experiments, and MR analyses to bridge mechanistic insights with clinical translation. Substantial evidence indicates that modifications in dietary and lifestyle habits can influence cognitive function, with certain nutrients contributing to the maintenance of neuronal homeostasis and the mitigation of cognitive decline. Nutritional intervention influences cognition and AD by modulating the gut microbiota, whose metabolites affect brain function via the gut‐brain axis. However, for achieving long‐term improvements in gut microbiota, a whole‐diet approach may hold greater promise than individual or combined nutrient supplementation. Overall, the gut microbiota constitutes a critical factor that must be considered in future research on the impact of diet on cognitive function. Consequently, a deeper understanding of the underlying mechanisms governing the interactions among nutrition, the microbiota, and the human body—through basic, clinical, and translational research—is essential to develop effective nutritional strategies for the comprehensive prevention and management of AD. Author Contributions Conceptualization and literature review: Binyue Xu and Xuhuan Li; Literature review: Shangling Dong, Zheyuan Zhang, and Dong Jin; Figure design and visualization: Binyue Xu; Original draft preparation: Binyue Xu and Guoping Li; Review and editing: Jiesheng Wang. All authors have read and agreed to the published version of the manuscript. Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest.